<div>Even though there has been a decrease in both infection rates and
prevalence of COVID-19 in some parts of the world, in some countries the
spread of COVID-19 has not been adequately controlled and the numbers
are still rising. Epidemiologists have warned of possible subsequent
waves until an effective vaccination becomes available. Until then,
recommendations for different aspects of patient care are strictly
needed, which underlines the importance of the COVID-19 series of
publications in this journal. The recommendations provided in these
articles will inform allergists and healthcare providers on the
management and treatment of patients during this pandemic. It should be
noted that these statements are based on current evidence and medical
knowledge and there is a paucity of prospective clinical trials
regarding some of the information provided in these documents. These
clinical statements need to be regularly updated with incoming new
clinical data.</div><div>Figure 1. Picture representing the wide range of clinical aspects
involved in the pathogenesis of COVID-19.</div><div>References</div><div>1. Coronavirus disease (COVID-2019) situation reports.
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports,
Accessed on 16 Apr 2020.</div><div>2. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140
patients infected with SARS-CoV-2 in Wuhan, China. <i>Allergy.</i> 2020.</div><div>3. Jesenak M, Banovcin P, Diamant Z. COVID-19, chronic inflammatory
respiratory diseases and eosinophils - Observationsfrom reported
clinical case series. <i>Allergy.</i> 2020.</div><div>4. Zhang M, Guogang X, Fengming D, al. e. The role of peripheral blood
eosinophil counts in COVID-19 patients. Allergy. 2020 (in press).</div><div>5. Dong X, Cao YY, Lu XX, et al. Eleven faces of coronavirus disease
2019. <i>Allergy.</i> 2020.</div><div>6. Zhang JJ, Cao YY, Dong X, et al. Distinct characteristics of COVID-19
patients with initial rRT-PCR-positive and rRT-PCR-negative results for
SARS-CoV-2. <i>Allergy.</i> 2020.</div><div>7. Du H, Dong X, Zhang JJ, et al. Clinical characteristics of 182
pediatric COVID-19 patients with different severities and allergic
status. <i>Allergy.</i> 2020.</div><div>8. Sokolowska M, Agache I, Akdis CA. Immune response in Covid-19:
mechanisms, clinical outcome, diagnostics and perspectives – an EAACI
report. Allergy. 2020 (in press).</div><div>9. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and
mechanisms of immunopathological changes in COVID-19. <i>Allergy.</i>2020.</div><div>10. Gursel M, Gursel I. Is global BCG vaccination-induced trained
immunity relevant to the progression of SARS-CoV-2 pandemic?<i>Allergy.</i> 2020.</div><div>11. Ozdemir C, Kucuksezer UC, Tamay ZU. Is BCG vaccination affecting the
spread and severity of COVID-19? <i>Allergy.</i> 2020.</div><div>12. Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147,
CD26 and other SARS-CoV-2 associated molecules in tissues and immune
cells in health and in asthma, COPD, obesity, hypertension, and COVID-19
risk factors. <i>Allergy.</i> 2020.</div><div>13. Cai Q, Huang D, Ou P, et al. COVID-19 in a designated infectious
diseases hospital outside Hubei Province, China. <i>Allergy.</i> 2020.</div><div>14. Bonini S, Maltese G. COVID-19Clinical trials: quality matters more
than quantity. <i>Allergy.</i> 2020.</div><div>15. Sotgiu G, Gerli AG, Centanni S, et al. Advanced forecasting of
SARS-CoV-2-related deaths in Italy, Germany, Spain, and New York State.<i>Allergy.</i> 2020.</div><div>16. Bousquet J, Jutel M, al. ACe. ARIA-EAACI statement on Asthma and
COVID-19. Allergy 2020 (submitted). .</div><div>17. Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A. Is asthma
protective against COVID-19? <i>Allergy.</i> 2020.</div><div>18. Johnston SL. Asthma and COVID-19: is asthma a risk factor for severe
outcomes? Allergy 2020 (in press).</div><div>19. Leonardi A, Fauquert JL, Doan S, et al. Managing ocular allergy in
the time of COVID-19. <i>Allergy.</i> 2020.</div><div>20. Licari A, Votto M, Brambilla I, et al. Allergy and asthma in
children and adolescents during the COVID outbreak: What we know and how
we could prevent allergy and asthma flares. <i>Allergy.</i> 2020.</div><div>21. Bousquet J, Akdis C, Jutel M, et al. Intranasal corticosteroids in
allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI
statement. <i>Allergy.</i> 2020.</div><div>22. Klimek L, Jutel M, Akdis C, et al. Handling of allergen
immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement.<i>Allergy.</i> 2020.</div><div>23. Pfaar O, Klimek L, Jutel M, et al. COVID-19 pandemic: Practical
considerations on the organization of an allergy clinic - an EAACI/ARIA
Position Paper. <i>Allergy.</i> 2020.</div><div>24. Klimek L, Jutel M, Bousquet J, al. e. Treatment of chronic
rhinosinusitis with nasal polyps (CRSwNP) in the COVID-19 pandemic – An
EAACI Position Paper. Allergy 2020 (submitted).</div><div>25. Brough HA, Kalayci O, Sediva A, et al. Managing childhood allergies
and immunodeficiencies during respiratory virus epidemics - The 2020
COVID-19 pandemic: A statement from the EAACI-section on pediatrics.<i>Pediatr Allergy Immunol.</i> 2020.</div><div>26. Untersmayr E, al. e. Immunology of COVID-19: mechanisms, clinical
outcome, diagnostics and perspectives – a report of the European
Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020.</div><div>27. Gelincik A, Brockow K, Celik GE, et al. Diagnosis and management of
the drug hypersensitivity reactions in Coronavirus disease 19.<i>Allergy.</i> 2020.</div><div>28. Vultaggio A, Agache I, Akdis CA, et al. Considerations on
Biologicals for Patients with allergic disease in times of the COVID-19
pandemic: an EAACI Statement. <i>Allergy.</i> 2020.</div><div>29. Riggioni C, Comberiati P, Giovannini M, et al. A compendium
answering 150 questions on COVID-19 and SARS-CoV-2. <i>Allergy.</i>2020.</div><div>30. Allergy homepage.
https://onlinelibrary.wiley.com/doi/toc/10.1111/(ISSN)1398-9995.COVID-19.
Accessed on 16 Jun 2020.</div><div>Disclosure of conflict of interests:</div><div>Dr. Pfaar reports grants and/or personal fees from ALK-Abelló,
Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie
GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biomay,
Circassia, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, MEDA
Pharma/MYLAN, Anergis S.A., Mobile Chamber Experts (a GA2LEN Partner),
Indoor Biotechnologies, GSK, Astellas Pharma Global, EUFOREA, ROXALL,
NOVARTIS, SANOFI AVENTIS, Med Update Europe GmbH, and streamedup! GmbH.
Dr. Torres has no conflict of interest in relation to this work. Dr.
Akdis reprots grants from Allergopharma, Idorsia, Swiss National Science
Foundation, Christine Kühne-Center for Allergy Research and Education,
European Commission’s Horizon’s 2020 Framework Programme, Cure, Novartis
Research Institutes, AstraZeneca, SciBase, GSK, and other from Sanofi
and Regeneron.</div>